Mohammad Asim Nisar, MD
Psychiatry · Okeechobee, FLNPI 1437444791
Payments from drug & device makers
Across 971 payments — averaging $6295.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2M
- Teva Pharmaceuticals USA, Inc.$1.5M
- AbbVie$1.3M
- Janssen Research & Development, LLC$261K
- Boehringer Ingelheim$197K
- Boehringer Ingelheim International GmbH$154K
- plus $701K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 13 | $1,973,824 |
| Teva Pharmaceuticals USA, Inc. | 161 | $1,517,667 |
| AbbVie | 134 | $1,308,493 |
| Janssen Research & Development, LLC | 35 | $261,006 |
| Boehringer Ingelheim | 23 | $196,610 |
| Boehringer Ingelheim International GmbH | 193 | $153,849 |
| Acadia Pharmaceuticals Inc | 30 | $123,725 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 58 | $109,358 |
| Otsuka America Pharmaceutical, Inc. | 129 | $109,263 |
| Avanir Pharmaceuticals, Inc. | 33 | $107,818 |
| Corcept Therapeutics | 30 | $97,323 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $65,826 |
| Neurocrine Biosciences, Inc. | 48 | $43,394 |
| Hoffmann-la Roche Limited | 14 | $42,833 |
| Johnson & Johnson | 16 | $625 |
| Alkermes, Inc. | 17 | $408 |
| Sunovion Pharmaceuticals Inc. | 9 | $124 |
| Lundbeck LLC | 6 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $90 |
| Axsome Therapeutics, Inc. | 1 | $79 |
| Abiomed | 2 | $34 |
| Almatica Pharma LLC | 2 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Eisai Inc. | 2 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
How this compares
$6,112,558 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Okeechobee
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.